オシメルチニブ医薬品の世界市場レポート 2025年

オシメルチニブ医薬品市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は15.8%で140億5,000万米ドルに成長します。予測期間の成長は、患者中心のケア強化、継続的な臨床試験と研究、精密医療の統合、価格設定とアクセスへの取り組み、世界の市場拡大に起因すると考えられます。予測期間の主な動向には、バイオシミラー参入と市場競争、リキッドバイオプシーの採用、ゲノムプロファイリングの進歩、耐性管理戦略、免疫療法併用試験などがあります。

肺がん罹患率の増加が予想され、オシメルチニブ医薬品市場の成長を牽引するとみられます。肺組織、特に気道を覆う細胞に発生する肺がんは、がん細胞の増殖と拡散に関与する特定のタンパク質を阻害する治療薬であるオシメルチニブの標的です。米国がん協会によると、米国では2022年に肺がんと診断された患者数は236,740人で、2023年には238,340人に増加します。その結果、肺がん罹患率の上昇は、オシメルチニブ医薬品市場の成長を促進する重要な要因となっています。

肺がんの治療とケアを強化することを目的とした組織のイニシアチブの高まりは、今後数年間のオシメルチニブ医薬品市場の成長を大きく促進すると予想されます。このような取り組みには通常、肺がんと診断された患者に対するケアの利用しやすさ、手ごろな価格、質の向上を目的とした政策、資金提供、プログラムの実施が含まれます。例えば、2024年5月、オーストラリア保健高齢者医療省は、低線量コンピュータ断層撮影（LDCT）スキャンを用いた肺がんの早期発見のための構造化されたアプローチを採用する全国肺がん検診プログラム（NLCSP）を開始しました。このプログラムは、特に喫煙歴のある50歳から80歳の高リスク者を対象としています。肺がんの標的治療薬であるオシメルチニブの利用を最適化するためのこのような組織的取り組みは、治療成績の改善へのコミットメントを強調するものです。したがって、こうした取り組みがオシメルチニブ医薬品市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オシメルチニブ医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のオシメルチニブ医薬品市場：成長率分析
• 世界のオシメルチニブ医薬品市場の実績：規模と成長, 2019-2024
• 世界のオシメルチニブ医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界オシメルチニブ医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオシメルチニブ医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 40mg
• 80mg
• 世界のオシメルチニブ医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストアと小売薬局
• オンライン薬局
• 世界のオシメルチニブ医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所進行非小細胞肺がん（NSCLC）
• 転移性非小細胞肺がん（NSCLC）
• その他の用途

第7章 地域別・国別分析

• 世界のオシメルチニブ医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオシメルチニブ医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オシメルチニブ医薬品市場：競合情勢
• オシメルチニブ医薬品市場：企業プロファイル
  • Syndax Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sandoz International GmbH
• Incyte Corporation
• Dr. Reddys Laboratories Ltd.
• Cipla Limited
• Seagen Inc.
• Zydus Lifesciences Limited
• Sun Pharmaceutical Industries Ltd.
• Alembic Pharmaceuticals Limited
• Aristo Pharmaceuticals Private Limited
• Incepta Pharmaceuticals Ltd.
• Accord Healthcare Limited
• Asmo Corporation
• Beacon Pharmaceutical Limited
• Clearsynth Labs Limited
• Apino Pharma Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オシメルチニブ医薬品市場2029：新たな機会を提供する国
• オシメルチニブ医薬品市場2029：新たな機会を提供するセグメント
• オシメルチニブ医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Osimertinib is a medication prescribed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific abnormal epidermal growth factor (EGFR) genes. As a kinase inhibitor, it functions by blocking the action of the abnormal protein that signals cancer cells to multiply.

The main types of osimertinib drugs are available in 40mg and 80mg dosages. The 40mg designation represents the strength of the Osimertinib tablet. These medications are distributed through various channels, including hospital pharmacies, drugstores, retail pharmacies, and online pharmacies, catering to conditions such as locally advanced non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer (NSCLC), and others.

The osimertinib drugs market research report is one of a series of new reports from The Business Research Company that provides osimertinib drugs market statistics, including osimertinib drugs industry global market size, regional shares, competitors with an osimertinib drugs market share, detailed osimertinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osimertinib drugs industry. This osimertinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osimertinib drugs market size has grown rapidly in recent years. It will grow from $6.66 billion in 2024 to $7.82 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to r&d investment and innovation, targeted therapy introduction, clinical trial success, resistance to previous treatments, improved safety profile.

The osimertinib drugs market size is expected to see rapid growth in the next few years. It will grow to $14.05 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to patient-centric care enhancement, continued clinical trials and research, precision medicine integration, pricing and access initiatives, global market expansion. Major trends in the forecast period include biosimilar entry and market competition, liquid biopsy adoption, genomic profiling advancements, resistance management strategies, immunotherapy combination trials.

The anticipated rise in the incidence of lung cancer is set to drive the growth of the osimertinib drug market. Lung cancer, originating in the lung tissues, particularly in cells lining the airways, is a target for osimertinib, a therapeutic drug that blocks specific proteins involved in the growth and spread of cancer cells. According to the American Cancer Society, the United States witnessed around 236,740 diagnosed lung cancer cases in 2022, a number that has increased to 238,340 by 2023. Consequently, the escalating incidence of lung cancer stands as a significant factor propelling the osimertinib drug market's growth.

The growing initiatives from organizations aimed at enhancing lung cancer care and treatment are anticipated to significantly drive the growth of the osimertinib drug market in the coming years. These initiatives typically involve the implementation of policies, funding, and programs designed to improve the accessibility, affordability, and quality of care for individuals diagnosed with lung cancer. For instance, in May 2024, the Australian Department of Health and Aged Care launched the National Lung Cancer Screening Program (NLCSP), which employs a structured approach for the early detection of lung cancer using low-dose computed tomography (LDCT) scans. This program specifically targets high-risk individuals, particularly those aged 50 to 80 with a substantial smoking history. Such organizational efforts to optimize the utilization of osimertinib, a targeted therapy for lung cancer, highlight the commitment to improving treatment outcomes. Therefore, these initiatives are propelling the growth of the osimertinib drug market.

Major companies in the osimertinib drugs market are increasingly focused on targeted therapies to enhance outcomes for patients with non-small cell lung cancer (NSCLC), especially those harboring EGFR mutations. This focus aims to improve treatment effectiveness and the overall quality of life for patients. Companies are also dedicating resources to clinical trials and research collaborations to broaden the indications for osimertinib and assess its efficacy in combination with other therapies for more comprehensive patient benefits. For instance, in September 2024, AstraZeneca Pharmaceuticals LP announced the launch of osimertinib (Tagrisso) for adults with locally advanced, unresectable NSCLC with specific EGFR mutations, following FDA approval. This approval came after a clinical trial showed significant improvements in progression-free survival compared to placebo, underscoring the potential of osimertinib as a vital treatment option for this patient population.

In October 2022, Ikena Oncology collaborated with AstraZeneca to explore the potential combination of IK-930 and osimertinib for enhanced efficacy and safety in treating EGFR-mutated non-small-cell lung cancer (NSCLC). This collaboration is a strategic move to leverage the expertise of both companies in advancing treatment options.

Major companies operating in the osimertinib drugs market report are Syndax Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, AstraZeneca PLC, Amgen Inc., Sandoz International GmbH, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Cipla Limited, Seagen Inc., Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Accord Healthcare Limited, Asmo Corporation, Beacon Pharmaceutical Limited, Clearsynth Labs Limited, Apino Pharma Co. Ltd., Kay Biotech Private Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Array BioPharma Inc., Dolphin Pharmaceutical Limited, Hetero Drugs Ltd., Serum Biotech Limited, Zenix Remedies, Accure Labs Pvt. Ltd.

North America was the largest region in the osimertinib drugs market in 2024. The regions covered in the osimertinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the osimertinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The osimertinib drugs market consists of sales of tagrisso, osi-TKI, and osimertinib mesylate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osimertinib Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osimertinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osimertinib drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osimertinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 40 mg; 80 mg
• 2) By Distribution Channel: Hospital Pharmacy; Drug Store And Retail Pharmacy; Online Pharmacy
• 3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC); Other Applications
• Companies Mentioned: Syndax Pharmaceuticals Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; AstraZeneca plc; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osimertinib Drugs Market Characteristics

3. Osimertinib Drugs Market Trends And Strategies

4. Osimertinib Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Osimertinib Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osimertinib Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osimertinib Drugs Market Growth Rate Analysis
• 5.4. Global Osimertinib Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osimertinib Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osimertinib Drugs Total Addressable Market (TAM)

6. Osimertinib Drugs Market Segmentation

• 6.1. Global Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 40 mg
• 80 mg
• 6.2. Global Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Drug Store And Retail Pharmacy
• Online Pharmacy
• 6.3. Global Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
• Metastatic Non-Small Cell Lung Cancer (NSCLC)
• Other Applications

7. Osimertinib Drugs Market Regional And Country Analysis

• 7.1. Global Osimertinib Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osimertinib Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osimertinib Drugs Market

• 8.1. Asia-Pacific Osimertinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osimertinib Drugs Market

• 9.1. China Osimertinib Drugs Market Overview
• 9.2. China Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osimertinib Drugs Market

• 10.1. India Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osimertinib Drugs Market

• 11.1. Japan Osimertinib Drugs Market Overview
• 11.2. Japan Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osimertinib Drugs Market

• 12.1. Australia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osimertinib Drugs Market

• 13.1. Indonesia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osimertinib Drugs Market

• 14.1. South Korea Osimertinib Drugs Market Overview
• 14.2. South Korea Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osimertinib Drugs Market

• 15.1. Western Europe Osimertinib Drugs Market Overview
• 15.2. Western Europe Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osimertinib Drugs Market

• 16.1. UK Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osimertinib Drugs Market

• 17.1. Germany Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osimertinib Drugs Market

• 18.1. France Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osimertinib Drugs Market

• 19.1. Italy Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osimertinib Drugs Market

• 20.1. Spain Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osimertinib Drugs Market

• 21.1. Eastern Europe Osimertinib Drugs Market Overview
• 21.2. Eastern Europe Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osimertinib Drugs Market

• 22.1. Russia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osimertinib Drugs Market

• 23.1. North America Osimertinib Drugs Market Overview
• 23.2. North America Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osimertinib Drugs Market

• 24.1. USA Osimertinib Drugs Market Overview
• 24.2. USA Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osimertinib Drugs Market

• 25.1. Canada Osimertinib Drugs Market Overview
• 25.2. Canada Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osimertinib Drugs Market

• 26.1. South America Osimertinib Drugs Market Overview
• 26.2. South America Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osimertinib Drugs Market

• 27.1. Brazil Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osimertinib Drugs Market

• 28.1. Middle East Osimertinib Drugs Market Overview
• 28.2. Middle East Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osimertinib Drugs Market

• 29.1. Africa Osimertinib Drugs Market Overview
• 29.2. Africa Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osimertinib Drugs Market Competitive Landscape And Company Profiles

• 30.1. Osimertinib Drugs Market Competitive Landscape
• 30.2. Osimertinib Drugs Market Company Profiles
  • 30.2.1. Syndax Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Osimertinib Drugs Market Other Major And Innovative Companies

• 31.1. Sandoz International GmbH
• 31.2. Incyte Corporation
• 31.3. Dr. Reddys Laboratories Ltd.
• 31.4. Cipla Limited
• 31.5. Seagen Inc.
• 31.6. Zydus Lifesciences Limited
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Alembic Pharmaceuticals Limited
• 31.9. Aristo Pharmaceuticals Private Limited
• 31.10. Incepta Pharmaceuticals Ltd.
• 31.11. Accord Healthcare Limited
• 31.12. Asmo Corporation
• 31.13. Beacon Pharmaceutical Limited
• 31.14. Clearsynth Labs Limited
• 31.15. Apino Pharma Co. Ltd.

32. Global Osimertinib Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osimertinib Drugs Market

34. Recent Developments In The Osimertinib Drugs Market

35. Osimertinib Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Osimertinib Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osimertinib Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osimertinib Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer